FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Commentary|Videos|April 20, 2024
Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
Author(s)Grace Halsey
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Advertisement
"Everyone of us that sees patients has people come in and say, 'Dr Nissen, I tried statins, I cannot tolerate them; I won't take them.'"
Bempedoic acid, with or without ezetimibe, is an option any clinician who treats hyperlipidemia should be comfortable with, Nissen said in a recent interview with Patient Care.®
Nissen is Chief Academic Officer, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH and the primary investigator for the bempedoic acid and bempedoic acid plus ezetimibe clinical trial program, including CLEAR Outcomes.
Advertisement
Related to this article
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5